Remove 2010 Remove 2012 Remove Clinical Trials Remove Consumption
article thumbnail

Using Cannabis for ALS: Benefits, Research and Best Strains

Greencamp

In 2010, another pre-clinical study was also conducted on mice, and published in the American Journal of Hospice and Palliative Care. All these findings correlate with the conclusions of the scientists who were involved in the mice study from 2010. 16: Cannabis; June 2012, Pages 400-404.

Strains 94
article thumbnail

New Study: Demographic and policy-based differences in behaviors and attitudes towards driving after marijuana use: an analysis of the 2013–2017 Traffic Safety Culture Index

Cannabis Law Report

The authors share this view, assessing that the current evidence shows that marijuana can impair driving ability and increase crash risk, especially shortly after consumption. Marijuana Decriminalization, Medical Marijuana Laws, and Fatal Traffic Crashes in US Cities, 2010–2017. A meta-analysis by Asbridge et al. Accident Anal Prev.

Policy 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

years (Atakan 2012 ). Bostwick ( 2012 :174) notes that medical and recreational uses in the USA have now blended together and are becoming indistinguishable in the eyes of citizens. However, from 2010, a dramatic increase is observable in articles about medicinal cannabis in the publications under analysis.

article thumbnail

ElleVet Sciences Publishes Safety Study On CBD For Animals

Cannabis Law Report

Wakshlag is well-known in the veterinary medicine community as the first doctor to conduct an efficacy study in dogs in a clinical trial at Cornell using ElleVet CBD/CBDA on dogs with multi-joint discomfort. The clinical trial results confirmed more than 80% of dogs showed significant or dramatic improvement.

Safety 45
article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. YANINA PEPINO, PHD COURTNEY D.